Breaking the chronic cycle of inflammatory diseases.
Disease Focus
Chronic inflammatory diseases destroy lives every day. We are highly attuned to the serious comorbidities associated with chronic inflammatory diseases, and patients are often at risk for more than they may realize due to the limitations of treatments which only provide symptomatic relief.
Our goal is to develop accessible innovations that not only address the symptoms of chronic inflammatory disease, but also halt disease progression and prevent medical complications in the future.
Current candidate investigations include a small-molecule antagonist of MRGPRX2 (EVO756), targeting a receptor specific to mast cells and sensory neurons that initiates and perpetuates immune responses upon binding with its ligands, which drives a broad range of disorders.
An additional target of current investigations is IL-18, a pro-inflammatory cytokine of the IL-1 family that regulates various immune processes that drive inflammation and is a potent modulator of ongoing inflammation. We are targeting IL-18 with a long-acting injectable therapeutic, EVO301, a SAFA-IL-18BP fusion-protein that is designed to neutralize the IL-18 inflammatory pathway.